Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2014 2
2015 2
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Bennouna J, et al. Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16. Lancet Oncol. 2013. PMID: 23168366 Clinical Trial.
Observational study of adjuvant therapy with capecitabine in colon cancer.
Steffens CC, Tschechne B, Schardt C, Jacobs G, Valdix AR, Schmidt P, Hansen R, Kröning H, Wohlfarth T, Guggenberger D. Steffens CC, et al. Among authors: valdix ar. Curr Med Res Opin. 2015 Apr;31(4):731-41. doi: 10.1185/03007995.2015.1014030. Epub 2015 Feb 12. Curr Med Res Opin. 2015. PMID: 25651480
Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation study.
Stein A, Quidde J, Schröder JK, Göhler T, Tschechne B, Valdix AR, Höffkes HG, Schirrmacher-Memmel S, Wohlfarth T, Hinke A, Engelen A, Arnold D. Stein A, et al. Among authors: valdix ar. BMC Cancer. 2016 Feb 10;16:82. doi: 10.1186/s12885-016-2113-8. BMC Cancer. 2016. PMID: 26865161 Free PMC article.
Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study.
Stein A, Petersen V, Schulze M, Seraphin J, Hoeffkes HG, Valdix AR, Schroeder J, Herrenberger J, Boxberger F, Leutgeb B, Hinke A, Kutscheidt A, Arnold D. Stein A, et al. Among authors: valdix ar. Acta Oncol. 2015 Feb;54(2):171-8. doi: 10.3109/0284186X.2014.961649. Epub 2014 Oct 13. Acta Oncol. 2015. PMID: 25307517
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
Kubicka S, Greil R, André T, Bennouna J, Sastre J, Van Cutsem E, von Moos R, Osterlund P, Reyes-Rivera I, Müller T, Makrutzki M, Arnold D; ML18147 study investigators including AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, and AGMT groups. Kubicka S, et al. Ann Oncol. 2013 Sep;24(9):2342-9. doi: 10.1093/annonc/mdt231. Epub 2013 Jul 12. Ann Oncol. 2013. PMID: 23852309 Free article. Clinical Trial.